Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding 1.2 billion in 2012. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2012, R&D expenditure totaled close to 250 million, representing more than 20% of Group sales. The Group has total worldwide staff of close to 4,900 employees.